Related Experiment Video

Updated: May 13, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Vemurafenib for leptomeningeal melanomatosis

Niklas Schäfer1, Björn Scheffler, Moritz Stuplich

  • 1Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Centre, Bonn, Germany.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 6, 2013
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

Related Experiment Videos

Last Updated: May 13, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Age-associated epigenomic heterogeneity in papillary tumors of the pineal region: a multicenter YoungNOA investigation.

Acta neuropathologica communications·2026

Lomustine with or without procarbazine in recurrent glioblastoma-A propensity score matching analysis.

Neuro-oncology advances·2026

Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF).

BMC cancer·2026

End-of-life challenges in neuro-oncological patient care: A survey from the Junge Neuroonkologische Arbeitsgemeinschaft.

Neuro-oncology practice·2026

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.

Nature communications·2026

Regrowth Patterns in Glioblastoma-Survival and Predictors.

Cancer medicine·2026

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

The Patient Who Could Not Die.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

First draft genome sequence of the emerging sexually transmitted dermatophyte Trichophyton mentagrophytes genotype VII.

Medical mycology·2026

Tradeoffs between targeted and expanded testing strategies for influenza A(H5N1).

ASM case reports·2026

First cases of suspected sexual transmission of Trichophyton mentagrophytes genotypes VII and VIII in Orange County, California, USA.

ASM case reports·2026

Mechanism of microRNA-30b-5p enhancing the response of MDA-MB-231 cells to cisplatin by regulating RAP1B expression.

Experimental and therapeutic medicine·2026

Microscopic polyangiitis with pulmonary involvement: Case Report.

Frontiers in medicine·2026

Airborne Virus Shedding of Respiratory Syncytial Virus Compared to Influenza A Virus in Hospitalized Patients.

Journal of medical virology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us